Advanced Proteome Therapeutics Joins Johnson & Johnson Lab

Advanced Proteome Therapeutics (TSXV:APC) has been accepted into the Johnson & Johnson (NYSE:JNJ) innovation laboratories in Toronto.

As quoted in the press release:

Advanced Proteome Therapeutics, currently operating in Boston, MA, will join other select early stage companies at the state of the art facility in Toronto starting May 1.

“Being selected by the Johnson & Johnson Innovation team to join JLABS @ Toronto and locating among a talented and diverse peer group is both an honour and extremely validating for our company,” said Randal Chase, CEO of Advanced Proteome Therapeutics. “The work space and facilities allow us to continue advancing our research while being surrounded by fast growing and emerging companies.”

Click here to read the full press release.

Get the Latest Biotech Investing Stock Information

Get the latest information about companies associated with Biotech Investing delivered directly to your inbox.


By selecting company or companies above, you are giving consent to receive email from those companies. And remember you can unsubscribe at any time.


Leave a Reply